Ear specialist Otonomy Inc. raised $100 million in an upsized initial public offering (IPO) Wednesday, selling 6.25 million shares priced at $16 each and building on its substantial $45.9 million series C round, one of last year's top private financings. Read More
A morsel of phase IIa data from Arrowhead Research Corp. left investors wanting more and sparked analyst speculation about the potential of the firm's ARC-520, an RNAi-based candidate for hepatitis B virus (HBV). Read More
Insmed Inc. priced a $100.1 million public offering Wednesday, more than doubling its cash balance, to support work on Arikayce, which, after yielding mixed data earlier this year, now seems poised to become the first once-daily, inhaled antibiotic for nontuberculous mycobacteria (NTM) and Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients. Read More
Researchers have found a way to destroy tumors by directly injecting them with spores of Clostridium novyi, a bacterium that thrives in anaerobic conditions and, therefore, prefers exactly the kind of cancer that other therapies have a hard time getting to: the poorly vascularized core of large tumors. Read More
Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., said the National Institute of Allergy and Infectious Diseases exercised additional options to conduct phase I studies in man and efficacy studies in nonhuman primates to test an intramuscular formulation of BCX4430, the company's lead compound in its antiviral program, as well as to assess effective dose ranges and dose schedules. Read More
The FDA reopened the comment period for its draft guidance, titled "Best Practices in Developing Proprietary Names for Drugs," after some respondents expressed concerns that the original 60-day comment period ending July 28 was insufficient to provide a meaningful response. Read More
Pfizer Inc., of New York, reported top-line results from placebo-controlled studies of Lyrica (pregabalin) conducted in China in patients with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (pDPN) Read More
Ohr Pharmaceutical Inc., of New York, reported that additional interim data from the phase II IMPACT study evaluating squalamine eye drops (OHR-102) in wet age-related macular degeneration (AMD) showed improved best-corrected visual acuity (BCVA) in patients who received the combination of OHR-102 and Lucentis (ranibizumab, Read More
